Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186875 · ClinicalTrials.gov registry record · Phase 2
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00186875: Completed Phase 2 study, sponsored by St. Jude Children's Research Hospital.
NCT00186875 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186875, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: * To estimate the response rate for patients with refractory or relapsed ALL. * To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.
Primary Outcome
The "response rate" is defined as the proportion of participants who attain morphological complete remission after the re-induction Block C, inclusive of all patients who begin re-induction. Morphological complete remission was defined as \<5% blasts in bone marrow by morphology.
Interventions
- DRUG Etoposide, cytarabine, vincristine, dexamethasone
- DRUG methotrexate, teniposide, PEG-asparaginase
- DRUG mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
- DRUG L-asparaginase, erwinia asparaginase
- PROCEDURE chemotherapy, intrathecal chemotherapy, steroid therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2003-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT00186875 record still lists
NCT00186875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 5 interventions - of which Etoposide, cytarabine, vincristine, dexamethasone is the first listed.
NCT00186875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186875 about?
NCT00186875 is a clinical study titled "Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia". The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: * To estimate the response rate for patients with refra...
What is the current status of trial NCT00186875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2003-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00186875?
The interventions under investigation include: Etoposide, cytarabine, vincristine, dexamethasone (DRUG), methotrexate, teniposide, PEG-asparaginase (DRUG), mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine (DRUG), L-asparaginase, erwinia asparaginase (DRUG), chemotherapy, intrathecal chemotherapy, steroid therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00186875?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00186875's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia